Too many healthcare and life science startups fail for reasons that have little to do with science. Brilliant founders spend years reducing technical risk while leaving the greatest uncertainty untouched: whether the market will adopt their solution. The startup ecosystem often reinforces this behavior by celebrating fundraising, accelerator acceptance, and product development before sufficient evidence exists that the right problem is being solved for the right stakeholders. We believe there is a better way. Progress should be measured by evidence, not activity. Market readiness should precede investor readiness. Capital should follow learning, not assumptions.
While most advisors help founders answer questions, Keystone Life Sciences helps founders decide which questions deserve answers prior to burning time, energy, or money.
We’re currently building the “operating system” for scale. Stay tuned for more information.
